Butler University's plans to renovate and expand Clowes Memorial Hall, including the addition of a ballroom space, aim to ...

On an investment spree with billions of dollars’ worth of projects ongoing globally, Indianapolis-based Eli Lilly and Company ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a global pharmaceutical firm, announced today the inauguration of the Lilly Seaport Innovation Center (LSC) in Boston's... Eli Lilly and ...

Eli Lilly said it received Food and Drug Administration ... is now approved to treat two types of inflammatory bowel disease in the U.S., the Indianapolis company said Wednesday.

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

With a market cap of $759.4 billion, Eli Lilly operates across diverse therapeutic areas, providing cutting-edge solutions in oncology, diabetes, immunology, and neuroscience. The Indianapolis ...

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.

Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer treatment program in a deal worth up to $2.5 billion. The Indianapolis-based ...

Shares of Eli Lilly and Co. fell more than 7% in midday trading Tuesday after the Indianapolis company announced its fourth quarter revenue would fall short of expectations. Lilly said its U.S ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...